Description
Haematex Research Pty Ltd was formed in Sydney in 2004 by scientists from Australian hospital
laboratories and Gradipore/Life Diagnostics. Gradipore had international success in commercializing
the dilute Russells viper venom (RVV) test for lupus anticoagulants and we have developed this
further to a liquid stable and more specific system.
Our projects have included developing a factor Xa activated clotting test (XACT) for procoagulant
phospholipid (PPL test) licenced to Diagnostica Stago. This detects prothrombotic risk in cancer and
(probably) cardiac disease.
We have also assisted Hyphen BioMed, Sysmex, Enzyme Research Lab and others in successful R&D projects. We have developed methods for collagen, ellagic acid complex and other compounds useful in coagulation testing and blood/biomaterials
research.
Our special interest is in the development of improved tests for bleeding and clotting disorders.
Especially for acquired and therapeutic coagulation inhibitors. Thus, we have novel APTT reagents
and a RVV-based test for all the new direct oral anticoagulants (DOACs).
Most recently we have developed DOAC Stop™, an activated carbon product which specifically
withdraws DOACs from patient samples, thus allowing valid routine tests to be carried out despite
the initial presence of DOACs. We would be delighted to interact with any like-minded researchers.
Selected Research
2019
Clotting tests correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent.
Thrombosis Research. 2019; 179: 69-72.
Exner T, Favresse J, Lessire S, Douxfils J, Mullier F.
2018
Simple method for removing DOACs
from plasma samples.
Thrombosis Research. 2018; 163: 117-122.
Exner T, Michalopoulos N, Pearce J, Xavier R, Ahuja M.
2017
An optimized dRVVT-based assay to estimate the
intensity of anticoagulation in patients treated with direct oral anticoagulants.
Thrombosis Research. 2017; 157: 29-37.
Sennesael AL, Exner T, Chatelain B, Lessire S, Larock AS, Vancraeynest C, Pochet L, Dogne JM, Spinewine A, Mullier F, Douxfils J.
2013
Testing for new oral anticoagulants with LA-resistant Russells viper venom reagents. An in vitro study
Thromb Haemost. 2013 Apr;109(4):762-5. doi: 10.1160/TH12-11-0842. Epub 2013 Jan 31.
Thomas Exner, Lisa Ellwood, Jenny Rubie, Aileen Barancewicz
2009
Clinical evaluation of a new functional test for detection of plasma procoagulant phospholipids
Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 08/2009; 20(7):494-502. DOI: 10.1097/MBC.0b013e32832c5e51
Patrick van Dreden · Aurélie Rousseau · Sylviane Fontaine · Barry J Woodhams · Thomas Exner
2005
Increased procoagulant phospholipid activity in blood from patients with suspected acute coronary syndromes: A pilot study
Blood Coagulation and Fibrinolysis 08/2005; 16(5):375-9. DOI:10.1097/01.mbc.0000173465.45613.a3.
Thomas Exner · Joanne E Joseph · David Connor · Joyce Low · David D F Ma
2004
A new activated factor X-based clotting method with improved specificity for procoagulant phospholipid
Blood Coagulation and Fibrinolysis 01/2004; 14(8):773-9. DOI:10.1097/01.mbc.0000061366.73802.df
Thomas Exner · Joanne Joseph · Joyce Low · David Connor · David Ma
2000
Conceptions and Misconceptions in Testing for Lupus Anticoagulants
Journal of Autoimmunity 10/2000; 15(2):179-83. DOI:10.1006/jaut.2000.0392
Thomas Exner
1999
Detecting APC-resistant factor V
Blood Coagulation and Fibrinolysis 10/1999; 10(6):359-66. DOI:10.1097/00001721-199909000-00006
D B Rylatt · C Hohnen-Behrens · R L Pilgrim · L E Dickeson · M Neal · T Exner ·
A monoclonal antibody against prothrombin fragment 1 behaves like a lupus anticoagulant (Letter)
Thrombosis and Haemostasis 04/1999; 81(3):470-1.
T Exner · M Kraus ·
1991
Guidelines for Testing and Revised Criteria for Lupus Anticoagulants (SSC Subcommittee for standardization of Lupus Anticoagulants.)
Thrombosis and Haemostasis. 1991; 65; 320-322.
T Exner · Triplett DA · Taberner D · Machin SJ
